2026-10-13T16:44:36Z https://api.figshare.com/v2/oai

oai:figshare.com:article/33950290 2026-09-21T05:45:41Z category_19 portal_316 item_type_3 month_year_09_2026

Data Sheet 1_Cost-effectiveness of pembrolizumab plus weekly paclitaxel for PD-L1–positive platinum-resistant recurrent ovarian cancer in the United States and China.pdf Feng Xuan (129437) Haoze Bian (24334970) Minguang Huang (22406680) Yan Yang (33204) Guodong Wang (115333) Pharmacology cost-effectiveness analysis incremental cost-effectiveness ratio partitioned survival model pembrolizumab platinum-resistant ovarian cancer quality-adjusted life-years Background<p>Pembrolizumab plus weekly paclitaxel, with or without bevacizumab, improves survival in programmed death ligand 1 (PD-L1)–positive platinum-resistant recurrent ovarian cancer, but its economic value remains uncertain. This study evaluated the cost-effectiveness of pembrolizumab plus weekly paclitaxel versus placebo plus weekly paclitaxel in patients with PD-L1 combined positive score ≥1 platinum-resistant recurrent ovarian cancer from the Chinese and United States (US) healthcare system perspectives.</p>Methods<p>A partitioned survival model was developed using data from ENGOT-ov65/KEYNOTE-B96. Outcomes included costs, life-years (LYs), quality-adjusted life-years (QALYs), incremental cost-effectiveness ratios (ICERs), incremental net monetary benefits (INMBs), and incremental net health benefits (INHBs). Cost-effectiveness was assessed against willingness-to-pay (WTP) thresholds of $27,906/QALY in China and $150,000/QALY in the US. Deterministic and probabilistic sensitivity analyses, scenario analyses, and subgroup analyses were performed.</p>Results<p>In China, pembrolizumab plus weekly paclitaxel increased costs from $31,241.22 to $127,168.48 and increased outcomes from 1.57 to 2.11 LYs and from 1.02 to 1.34 QALYs, yielding 0.54 additional LYs and 0.32 additional QALYs. The ICER was $295,671.88/QALY, with an INMB of −$86,873.48 and an INHB of −3.11 QALYs. In the US, costs increased from $199,488.96 to $451,893.63, and outcomes increased from 1.59 to 2.15 LYs and from 1.03 to 1.37 QALYs. The ICER was $746,255.61/QALY, with an INMB of −$201,670.44 and an INHB of −1.34 QALYs. Pembrolizumab cost and health-state utilities were the main ICER drivers. Probabilistic sensitivity analysis showed 0% cost-effectiveness probability at both WTP thresholds. Scenario and subgroup analyses confirmed the base-case findings. At current bevacizumab prices, pembrolizumab prices would need substantial reductions to meet country-specific WTP thresholds.</p>Conclusion<p>Compared with placebo plus weekly paclitaxel, pembrolizumab plus weekly paclitaxel improved survival and QALYs in patients with PD-L1–positive platinum-resistant recurrent ovarian cancer but was unlikely to be cost-effective at current prices in either China or the US.</p> 2026-09-21T05:45:41Z Dataset Dataset 10.3389/fphar.2026.1926275.s001 https://figshare.com/articles/dataset/Data_Sheet_1_Cost-effectiveness_of_pembrolizumab_plus_weekly_paclitaxel_for_PD-L1_positive_platinum-resistant_recurrent_ovarian_cancer_in_the_United_States_and_China_pdf/33950290 CC BY 4.0